ENSC (Ensysce Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ENSC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | BOB G GOWER | Director | Buy | — | — |
| 2023-03-06 | BOB G GOWER | Director | Buy | — | — |
| 2023-03-02 | BOB G GOWER | Director | Buy | — | — |
| 2023-02-01 | BOB G GOWER | Director | Buy | — | — |
| 2022-06-27 | Adam Levin | Director | A | — | — |
| 2022-06-27 | Lee M. Rauch | Director | A | — | — |
| 2022-06-27 | Steven Robert Martin | Director | A | — | — |
| 2022-06-27 | Andrew Benton | Director | A | — | — |
| 2022-06-27 | William H Chang | Director | A | — | — |
| 2022-06-27 | BOB G GOWER | Director | A | — | — |
| 2022-06-27 | Curtis Rosebraugh | Director | A | — | — |
| 2022-05-27 | Lynn Kirkpatrick | Chief Executive Officer | Buy | — | — |
| 2022-02-24 | David Carl Humphrey | Chief Financial Officer | A | — | — |
| 2022-02-24 | Kevin Geoffrey Birkett | Chief Commercial Officer | A | — | — |
| 2022-02-24 | Lynn Kirkpatrick | Chief Executive Officer | A | — | — |
| 2022-02-04 | Adam Levin | Director | A | — | — |
| 2022-02-04 | David Carl Humphrey | Chief Financial Officer | A | — | — |
| 2022-02-04 | William H Chang | Director | A | — | — |
| 2022-02-04 | Andrew Benton | Director | A | — | — |
| 2022-02-04 | Linda Pestano | Chief Development Officer | A | — | — |
| 2022-02-04 | Steven Robert Martin | Director | A | — | — |
| 2022-02-04 | Curtis Rosebraugh | Director | A | — | — |
| 2022-02-04 | BOB G GOWER | Director | A | — | — |
| 2021-07-02 | David Carl Humphrey | Chief Financial Officer | A | — | — |
| 2021-07-02 | Steven Robert Martin | Director | A | — | — |
| 2021-07-02 | William H Chang | Director | A | — | — |
| 2021-07-02 | William K Schmidt | Chief Medical Officer | A | — | — |
| 2021-07-02 | Richard Chester Wright | Chief Business Officer | A | — | — |
| 2021-07-02 | Andrew Benton | Director | A | — | — |
| 2021-07-02 | Kevin Geoffrey Birkett | Chief Commercial Officer | A | — | — |
| 2021-07-02 | BOB G GOWER | Director | A | — | — |
| 2021-07-02 | Lynn Kirkpatrick | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 516,740 | — |
| — | Director | 721 | — |
| — | Chief Executive Officer | 99 | — |
| — | Chief Financial Officer | 14 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENSC quote page; the site-wide leaderboard is on the insider transactions hub.